Your browser doesn't support javascript.
loading
Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
Liu, Zhaozhen; Pang, Can; Deng, Yuchuan; Guo, Caiping; Li, Jia; Li, Yanping; Xin, Ruolei; Li, Xiyao; Xu, Conghui; Huang, Chun; Lu, Hongyan; Li, Jie.
Afiliação
  • Liu Z; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: lzz1036352615@163.com.
  • Pang C; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: pangcan89@163.com.
  • Deng Y; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: 934931612@qq.com.
  • Guo C; Department of Infectious Diseases and Medical Immunology, Beijing Youan Hospital, Capital Medical University, Beijing, China. Electronic address: gcpdt001@126.com.
  • Li J; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: lia118325@163.com.
  • Li Y; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: liyanping_117@126.com.
  • Xin R; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: xinruolei@sina.com.
  • Li X; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: xalixiyao@126.com.
  • Xu C; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: xuch@bjcdc.org.
  • Huang C; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: huangch@bjcdc.org.
  • Lu H; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: hongyan_lu@sina.com.
  • Li J; Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing, China. Electronic address: lijie304304@163.com.
Vaccine ; 41(34): 4978-4985, 2023 07 31.
Article em En | MEDLINE | ID: mdl-37394372
ABSTRACT

BACKGROUND:

A limited amount of information is available about the immunogenicity of the quadrivalent inactivated influenza vaccine among human immunodeficiency virus (HIV)-infected individuals, especially in low and middle-income countries (LMICs).

METHODS:

HIV-infected adults and HIV-uninfected adults received a dose of quadrivalent inactivated influenza vaccine including strains of H1N1, H3N2, BV and BY. Enzyme-linked immunosorbent assay (ELISA) and hemagglutination-inhibition assay (HAI) were used to determine IgA, IgG antibody concentration and geometric mean titers (GMT) at day 0 and day 28, respectively. Associated factors contributing to seroconversion or GMT changes were analyzed using simple logistic regression model.

RESULTS:

A total of 131 HIV-infected and 55 HIV-uninfected subjects were included in the study. In both HIV-infected and uninfected arms, IgG and IgA against influenza A and B all increased significantly at day 28 after receiving QIV (P < 0.001). GMTs of post-vaccination at day 28 showed that HIV-infected persons with CD4 + T cell counts ≤ 350 cells/mm3 were statistically less immunogenic to all strains of QIV than HIV-uninfected ones (P < 0.05). HIV-infected participants with CD4 + T cell counts ≤ 350 cells/mm3 were less likely to achieve seroconversion to QIV (H1N1, BY and BV) than HIV-uninfected individuals at day 28 after vaccination (P < 0.05). Compared with HIV-infected patients with baseline CD4 + T cell counts ≤ 350 cells/mm3, individuals with baseline CD4 + T cell counts > 350 cell/mm3 seemed more likely to generate antibody responses to H1N1 (OR2.65, 95 %CI 1.07-6.56) and BY (OR 3.43, 95 %CI 1.37-8.63), and showed a higher probability of seroconversion to BY (OR 3.59, 95 %CI 1.03-12.48). Compared with nadir CD4 + T cell count ≤ 350 cell/mm3, individuals with nadir CD4 + T cell count > 350 cell/mm3 showed a higher probability of seroconversion to H1N1(OR 3.15, 95 %CI 1.14-8.73).

CONCLUSION:

Influenza vaccination of HIV-infected adults might be effective despite variable antibody responses. HIV-positive populations with CD4 + T cell counts ≤ 350 are less likely to achieve seroconversion. Further vaccination strategies could be developed for those with low CD4 T cell counts.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Infecções por HIV / Soropositividade para HIV / Influenza Humana / Vírus da Influenza A Subtipo H1N1 Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Vaccine Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Infecções por HIV / Soropositividade para HIV / Influenza Humana / Vírus da Influenza A Subtipo H1N1 Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Revista: Vaccine Ano de publicação: 2023 Tipo de documento: Article